July 14, 2015, COLOGNE, Germany—Axiogenesis AG, a leading supplier of tissue-specific human cell types derived from induced pluripotent stem cells (iPSCs), and provider of pre-clinical drug development assays and disease models, announced today that it has signed an sublicense agreement with GE Healthcare (GEHC). Under the agreement, GEHC will sublicense intellectual property to use human iPSCs, enabling Axiogenesis to develop cellular assays and models derived from stem cells for use in drug discovery and toxicity screening for its customers. This agreement strengthens Axiogenesis’ ability to offer the market freedom-to-operate with Axiogenesis’ proprietary iPSC-derived cells and tissues.
[Read more…]
3 Eerie Similarities between the Acquisition of Cord Blood Registry® (CBR) and ViaCord
Cord Blood Registry® (CBR) recently made headlines by announcing that it had entered into a definitive agreement to be acquired by AMAG Pharmaceuticals for $700M. While the announcement was new, there were aspects of the deal that seemed eerily familiar.
[Read more…]
3 Eerie Similarities between the Acquisition of Cord Blood Registry® and ViaCord Â
Cord Blood Registry® recently made headlines by announcing that it had entered into a definitive agreement to be acquired by AMAG Pharmaceuticals. While the announcement was new, there were aspects of the deal that seemed eerily familiar.
CBR® Acquired by AMAG Pharma for Same Multiple on Revenue as PerkinElmer Paid for ViaCord
In particular, three aspects were strangely reminiscent of the deal in which PerkinElmer acquired the cord blood bank ViaCord in 2007.
[Read more…]
Global List of Cord Blood Banking Conferences & Events
As the cord blood banking marketplace has matured and attracted a wide range of industry participants, a variety of conferences and events to support the industry have also emerged, both in the United States and worldwide. Â Most of these conferences focus on the technical, ethical, and professional aspects of running cord blood banking businesses, but there are speakers that share research advances related to cord blood stem cells and cord blood transplant methodology.
CBR® Acquisition by AMAG Pharma Further Bolsters Cord Blood Investment Environment
The past few years have seen increasing investments made within the cord blood banking market, both by private equity and venture capital firms. These investments show the strength of the cord blood banking market. A summary of these investors is shown below.
There have also been significant acquisitions made within the cord blood industry, with the largest cord blood bank within the United States, Cord Blood Registry, recently acquired by AMAG Pharmaceuticals in June of 2015 for $700 million. The purchase valued Cord Blood Registry at over 5.55 times revenue and over 15.55 times EBITDA. Â [Read more…]
- « Previous Page
- 1
- …
- 305
- 306
- 307
- 308
- 309
- …
- 318
- Next Page »